Core Viewpoint - Medtide Inc. is positioned to leverage the growing demand for GLP-1 drugs as it aims for a breakthrough in the capital market following its successful hearing with the Hong Kong Stock Exchange [1][7]. Group 1: Market Position - Medtide Inc. ranks third globally in the peptide-focused CRDMO sector, holding a market share of 1.5%, significantly behind Bachem (13.8%) and PolyPeptide (10.0%) [2]. - The company has established a certain level of international competitiveness within the peptide CRDMO niche [2]. Group 2: Financial Performance - In 2022, Medtide reported revenues of 351 million RMB and a net profit of 53.98 million RMB, which slightly declined to 337 million RMB and 48.91 million RMB in 2023 [3]. - However, in the first half of 2024, revenues rebounded to 197 million RMB, marking a year-on-year increase of 21.23%, while net profit surged by 110.43% to 50.57 million RMB [3]. - The growth in 2024 is primarily driven by strong performance in overseas markets, particularly the U.S., where revenue increased by 165% to 122 million RMB, raising its contribution to total revenue from 28.2% to 61.8% [3]. Group 3: Capacity Expansion - To meet increasing market demand, Medtide is actively expanding its production capacity, with a cGMP facility in China covering over 15,000 square meters and equipped with 19 peptide synthesis lines and 16 purification lines [4]. - The company plans to build or acquire new production facilities in China within the next two to three years, potentially increasing annual production capacity by approximately 2,000 kg [4]. - In the U.S., Medtide acquired a production facility in Rocklin, California, with plans to complete construction by the second half of 2025, which is expected to add 100 to 300 kg to its annual capacity [4]. - As of December 31, 2024, Medtide's project pipeline includes 1,217 ongoing CRO projects and 332 ongoing CDMO projects, including 9 NCE GLP-1 molecule development projects [4]. Group 4: Risks and Challenges - Medtide faces challenges due to high customer concentration, with revenues from the top five clients accounting for 56.2% of total revenue in the first half of 2024, up from 36.5% in 2021 [6]. - The company's valuation has experienced significant fluctuations, reflecting complexities in capital operations, with notable transactions occurring in 2015, 2020, and 2021 [6].

转自：盐城市人民政府网站 | 索引号 | 11320900014355773E/2025-27099 | 组配分类 | 监管执法 | | --- | --- | --- | --- | | 发布机构 | 市市监局 | 发文日期 | 2025-05-30 | | 文号 | | 公开方式 | 主动公开 | | 主题分类 | 市场监管、安全生产监管 | | | | 时效 | 有效 | | | 特此通告。 盐城市市场监督管理局 近期，盐城市市场监督管理局完成2025年食品抽检任务692批次，涉及保健食品、饼干、餐饮食品、炒货食品及坚果食品、蛋制品、淀粉及淀粉制品、豆制 品、方便食品、蜂产品、糕点、罐头、酒类、冷冻饮品、粮食加工品、肉制品、乳制品、食品添加剂、食糖、食用农产品、食用油（油脂及其制品）、蔬菜 制品、薯类和膨化食品、水产制品、水果制品、速冻制品、糖果制品、调味品、饮料等27大类食品。检出其中食用农产品、餐饮食品、糕点3大类食品9批次 样品不合格，详细信息见附表。 针对监督抽检中发现的不合格食品，市市场监管局已责成相关县（区、市）市场监管部门立即组织开展处置工作，查清产品流向，督促企业采取下架、召回 不合格产 ...

商用航空发动机自主可控的重要性在于应对国际供应链风险，特别是美国可能 对中国商用航空发动机实施断供。这一事件催化了中国商用航空发动机自主可 控进程的加速。当前，中国商用航空发动机几乎全部依赖进口，包括国产飞机 C919 使用的 LEAP 发动机。如果断供，将对 C919 产生重大影响。因此，自 主可控成为迫切需求。 中国商用航空发动机市场空间有多大？ 根据测算，未来 20 年全球商用航空发动机市场需求约为 13 万亿元人民币，平 均每年 6,500 亿元人民币。中国市场预计总需求为 2.6 万亿元人民币，平均每 年 1,300 亿元人民币。这些数据反映了巨大的市场潜力。此外，维护费用通常 全球火炸药产能扩张面临瓶颈，美欧等国均面临短缺。欧盟推出 ISIP 法 案增加火炸药产能，美国加大对雷福德和霍尔斯顿弹药厂的投入，但扩 产难度大。 商业航天能力兴起推动国防体系建设，国防部门可购买太空发射能力和 商业星群。美国 Spacex 公司的"星链计划"和"星舰"超重型火箭试 验将极大推动低轨民用和军用星座建设。 Q&A 商用航空发动机自主可控的重要性及其加速的原因是什么？ 高于新机费用，使得整个生命周期内的市场规模更 ...

截至目前，已有广州悦好食品、上海紫河信息、久居香调味品、苏州贵和企业管理咨询服务、谨琰 （海口）国际贸易、乾程理想、鑫甲泰电子、江苏科朴纺织等40余家用人单位报名参加。 记者从郑州郑东新区组织人事和社会保障局获悉，6月7日，由郑州郑东新区组织人事和社会保障局 主办，丹尼斯奥莱天地、52就业网承办的"郑东新区2025年高校毕业生专场招聘会"将在丹尼斯七天地举 办，满足企事业单位的招聘和引才需求，吸引高校毕业生来郑东新区就业创业，为实现郑东新区高水平 发展提供有力人才支撑。 据了解，招聘会涵盖电子通信、商业服务、教育培训、生产制造、生物医药、文化传媒、食品、农 林牧、房地产、保险金融、物流等行业，提供近3500个就业岗位，涉及通信工程师、店长、外贸、财 务、文员、设备工程师、客服、IT技术、机械技术、销售、带货主播、新媒体运营、电商运营、平面设 计、渠道经理、课程顾问、市场专员等。 本报讯（记者 刘盼盼）6月3日，记者从郑州市二七区人力资源和社会保障局获悉，郑州市二七区 人力资源和社会保障局联合河南123人才网将于6月5日上午在郑州市二七区零工市场举办职引未来—— 大中城市联合招聘郑州市应往届高校毕业生专场招聘会 ...

Group 1 - The core focus of Wujiang is to achieve the "356" goal of new industrialization, emphasizing high-end textiles, new materials, new generation information technology, digital economy, new energy, and green low-carbon initiatives [1] - Wujiang aims to strengthen its four trillion-level industrial advantages and seize new opportunities in third-generation semiconductors, artificial intelligence, and low-altitude manufacturing [1] - The region has established a collaborative innovation ecosystem involving leading enterprises, research institutions, and various innovation entities, resulting in the formation of several task-oriented innovation alliances and benchmark incubators [1] Group 2 - Wujiang has cultivated 12 manufacturing champions and 77 national specialized and innovative "little giant" enterprises, leading the city in these categories [1] - The government plans to enhance the cultivation of technology-leading enterprises, unicorns, gazelles, and high-tech enterprises, aiming to exceed 15 national manufacturing champions and 100 specialized "little giant" enterprises [1] - Investment in research and experimental development is projected to exceed 11 billion yuan, with industrial technological transformation investments surpassing 18 billion yuan [1] Group 3 - To promote the deep integration of "hard manufacturing" and "soft manufacturing," Wujiang will implement a three-year plan to double modern service industries, focusing on R&D design, technology finance, information technology services, and certification [2] - The development of the Suzhou Bay Central Business District is a priority, aiming to transform manufacturing advantages into service industry strengths [2] - Wujiang seeks to create a high-quality development cluster for modern service industries [2]

根据普渡大学和芝加哥商品交易所集团的农业经济晴雨表，农民们对未来更为乐观。该指数在5月12-16 日期间对约400家生产商进行了调查，结果显示，预计未来五年农产品出口将增加的农民数量"急剧增 加"。然而，只有28%的人强烈同意"自由贸易有利于农业和大多数其他美国产业"——低于2020年11月 该说法首次提出时49%的农民同意这一说法。该晴雨表显示，结果"进一步证明生产者对贸易的看法已 经转变"。 ...

Core Viewpoint - 泰德医药 is positioned as the third largest global player in the peptide-focused CRDMO market, with a market share of 1.5% as of 2023, according to the Hong Kong Stock Exchange and Frost & Sullivan data [1][3]. Company Overview - 泰德医药 offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production, primarily focusing on CRO and CDMO services related to peptide NCE discovery and CMC development [3][4]. - The company has established stable customer relationships in over 50 countries, including major markets such as China, the US, Japan, Europe, South Korea, and Australia [3]. Market Position - The global peptide CRDMO market is dominated by two major players holding 23.8% of the market share, while the remaining participants, including 泰德医药, hold approximately 1% each [3]. - The global peptide drug market has grown from $60.7 billion in 2018 to $89.5 billion in 2023, with a compound annual growth rate (CAGR) of 8.1%, and is projected to reach $261.2 billion by 2032, with a CAGR of 12.6% [4]. Project Pipeline - As of December 31, 2024, 泰德医药 has a project pipeline consisting of 1,217 ongoing CRO projects and 332 ongoing CDMO projects, with a strategic focus on GLP-1 related projects [4]. Financial Performance - For the fiscal years 2022, 2023, and 2024, 泰德医药 reported revenues of approximately RMB 351 million, RMB 337 million, and RMB 442 million, respectively, with net profits of approximately RMB 54 million, RMB 49 million, and RMB 59 million [6].

Core Insights - The report highlights a positive outlook for various sectors, with specific companies identified as key investment opportunities based on their performance and market conditions [5][11][15][19][23][27][31][35][39][44]. Company Summaries 招商银行 (China Merchants Bank, 600036) - The bank's Q1 2025 performance showed a decline in revenue and net profit, with operating income at 837.51 billion yuan, down 3.09% year-on-year, and net profit at 372.86 billion yuan, down 2.08% [11]. - The bank maintains a high dividend payout ratio, with a projected dividend of 2 yuan per share for 2024, resulting in a dividend yield of 4.60% based on the May 29 closing price [11]. - The bank's asset quality remains under pressure, particularly in retail loans, with a non-performing loan ratio of 0.94% [11]. 紫金矿业 (Zijin Mining, 601899) - The company reported significant growth in mineral production, achieving 1.07 million tons of copper and 73 tons of gold in 2024, with production costs decreasing [15]. - Zijin Mining's resource reserves are expanding, with successful exploration projects and acquisitions enhancing its market position [15]. - The company expects continued growth in copper and gold prices, supporting its revenue projections for 2025 [15]. 三美股份 (Sanmei Co., 603379) - The company experienced a substantial increase in revenue from its refrigerant products, with a 30.28% year-on-year growth in 2024 [19]. - The average selling price of refrigerants rose significantly, contributing to improved profitability [19]. - The company is well-positioned in the refrigerant market, with ongoing price increases expected in 2025 [19]. 青岛啤酒 (Qingdao Beer, 600600) - The company reported a revenue of 321.38 billion yuan in 2024, with a net profit of 43.45 billion yuan, showing signs of recovery in the beverage sector [23]. - The management is optimistic about demand recovery as the peak season approaches, supported by favorable government policies [23]. - EPS projections for 2025 are set at 3.52 yuan, with a "buy" rating maintained [23]. 恒瑞医药 (Hengrui Medicine, 600276) - The company achieved a 20.14% year-on-year growth in revenue for Q1 2025, driven by its innovative drug portfolio [27]. - Hengrui's focus on R&D has led to the development of multiple new drugs, enhancing its market competitiveness [27]. - EPS for 2025 is projected at 1.05 yuan, with a "buy" rating maintained [27]. 海大集团 (Haida Group, 002311) - The company reported a 9% increase in feed sales in 2024, with significant growth in international markets [31]. - Haida is actively pursuing international expansion, particularly in Southeast Asia and Africa, to enhance its market presence [31]. - EPS projections for 2025 are set at 3.01 yuan, with a "buy" rating maintained [31]. 华电国际 (China Huadian Corporation, 600027) - The company completed a significant asset restructuring, expected to enhance its operational scale and market share [35]. - Post-restructuring, the company anticipates a 25.07% increase in revenue and a 5.93% increase in net profit [35]. - EPS projections for 2025 are set at 0.64 yuan, with a "buy" rating maintained [35]. 胜宏科技 (Shenghong Technology, 300476) - The company reported a 35.31% increase in revenue for 2024, driven by strong demand in the PCB sector [39]. - Q1 2025 saw an 80.31% increase in revenue, with significant growth in high-value product orders [39]. - EPS projections for 2025 are set at 5.09 yuan, with a "buy" rating maintained [39]. 中国电信 (China Telecom, 601728) - The company reported a 3.1% year-on-year increase in revenue, with a focus on digital transformation and service innovation [44]. - The mobile user base continues to grow, contributing to stable revenue streams [44]. - EPS projections for 2025 are set at 0.39 yuan, with a "buy" rating maintained [44].

证券研究报告 | 策略研究 gszqdatemark 2025 06 03 年 月 日 投资策略 6 月策略观点与金股推荐 6 月策略观点：题材交易可逐步提升风偏 大势研判：5 月市场表现看，交易难度较 4 月明显加大，大势层面表现在 指数连续两次冲高回落，配置层面则表现在交易主线的匮乏，题材数量不 少但持续性普遍不佳。此前我们也在分析中预测了一些市场可能进行交易 的方向，包括 5 月初相对低位的科技 TMT、5 月中旬的对美出口链修复， 但均始于"大胆假设"，结束于"小心求证"。站在当前时点，面对市场整 体存在阻力位压力、配置迟迟未见主线的情况，建议继续控制仓位、保持 耐心，同时做好准备，结合历史经验建立对未来行情的预期。参考历史表 现对今年 6 月行情进行展望，基准情形下，假设仍然没有重磅的事件催化， 梳理 2025 一季报看也仅有部分细分行业具备较好的景气度，整体可类比 2024 年 6 月情形，对应均衡配置仍然是重要策略：结合 2025 一季报与 行业中观数据挖掘产业景气；基于宏观叙事保有一定的防御仓位；题材交 易即使没有特别强的催化也可适当提升风偏，历史经验看近来每年 6 月， 题材交易都是重要方向 ...

策略早餐 主要品种策略早餐 （2025.06.03） 养殖、畜牧及软商品板块 品种：生猪 核心逻辑： 1、供应方面，截至 2025 年 4 月，据农业农村部数据，全国能繁母猪存栏量为 4038 万头，环比持平，同比增长 1.3%。这一数据反映出自 2024 年 4 月以来，产能 累计上升 1.3%，处于较为平稳的格局，暂未出现产能下滑的情况。而根据第三方机 构钢联数据及涌益咨询的数据显示，2025 年 4 月能繁母猪存栏量环比小幅上升，尽 管第三方机构与官方数据在统计口径上存在一定的差异，但环比上涨在一定程度上 体现了市场上暂无去产能的驱动，甚至部分企业开始缓慢恢复产能。5 月份看来， 生猪市场情绪支撑因素仍存，叠加仔猪价格暂未明显下跌，预计上有能繁母猪存栏 量或仍然稳中有增。根据产能数据推算的生猪供应量仍然充足，暂未看到供应量下 降的格局。 2、需求方面，从投机性需求来看，据钢联数据统计，5 月 23 日当周国内重点 屠宰企业的冻品库容率为 17.28%，与上一周持平，处于历史低位。当前由于需求表 现疲软，冻品市场需求暂未改善，出库维持缓慢节奏。而部分屠宰企业现品销售困 难，存在被动分割入库的情况，综合导致 ...